Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel Sells 34,800 Shares

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) CEO John D. Quisel sold 34,800 shares of the stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $55.33, for a total transaction of $1,925,484.00. Following the transaction, the chief executive officer directly owned 161,828 shares in the company, valued at $8,953,943.24. The trade was a 17.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Disc Medicine Price Performance

Shares of Disc Medicine stock traded up $0.83 during mid-day trading on Monday, reaching $57.74. 235,086 shares of the stock were exchanged, compared to its average volume of 338,655. The company has a market cap of $2.00 billion, a price-to-earnings ratio of -14.73 and a beta of 0.76. The company has a current ratio of 37.65, a quick ratio of 37.65 and a debt-to-equity ratio of 0.04. The firm has a 50-day simple moving average of $50.05 and a 200 day simple moving average of $51.61. Disc Medicine, Inc. has a fifty-two week low of $30.82 and a fifty-two week high of $68.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($1.02) EPS for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.03). On average, sell-side analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on IRON. BMO Capital Markets boosted their target price on shares of Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a research note on Monday, May 12th. Raymond James Financial initiated coverage on shares of Disc Medicine in a research note on Wednesday, June 11th. They set a "strong-buy" rating and a $89.00 price objective on the stock. Wedbush reaffirmed an "outperform" rating and set a $90.00 price target on shares of Disc Medicine in a research note on Monday, June 16th. Cantor Fitzgerald boosted their target price on shares of Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a report on Tuesday, March 18th. Finally, Morgan Stanley started coverage on Disc Medicine in a research report on Thursday, July 3rd. They issued an "overweight" rating and a $85.00 price target for the company. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Disc Medicine presently has a consensus rating of "Buy" and a consensus target price of $96.70.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Amalgamated Bank raised its holdings in Disc Medicine by 38.6% in the first quarter. Amalgamated Bank now owns 787 shares of the company's stock worth $39,000 after purchasing an additional 219 shares during the period. Tower Research Capital LLC TRC raised its holdings in Disc Medicine by 47.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock worth $52,000 after purchasing an additional 266 shares during the period. Teacher Retirement System of Texas raised its holdings in Disc Medicine by 8.9% in the fourth quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock worth $308,000 after purchasing an additional 396 shares during the period. Sterling Capital Management LLC raised its holdings in Disc Medicine by 798.4% in the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock worth $36,000 after purchasing an additional 503 shares during the period. Finally, Arizona State Retirement System raised its holdings in Disc Medicine by 12.5% in the first quarter. Arizona State Retirement System now owns 5,315 shares of the company's stock worth $264,000 after purchasing an additional 590 shares during the period. 83.70% of the stock is currently owned by institutional investors and hedge funds.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.